Abbott Laboratories (ABT) Position Lowered by Alpha Windward LLC

Alpha Windward LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 8.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,908 shares of the healthcare product maker’s stock after selling 342 shares during the quarter. Alpha Windward LLC’s holdings in Abbott Laboratories were worth $283,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABT. Bank of New York Mellon Corp increased its stake in Abbott Laboratories by 102,159.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 27,234,758 shares of the healthcare product maker’s stock worth $1,997,943,000 after purchasing an additional 27,208,125 shares in the last quarter. Capital International Investors grew its stake in shares of Abbott Laboratories by 257.0% during the 3rd quarter. Capital International Investors now owns 19,869,687 shares of the healthcare product maker’s stock worth $1,457,640,000 after acquiring an additional 14,303,610 shares in the last quarter. Matthew Goff Investment Advisor LLC grew its stake in shares of Abbott Laboratories by 5,999.0% during the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 6,418,950 shares of the healthcare product maker’s stock worth $105,246,000 after acquiring an additional 6,313,704 shares in the last quarter. Vanguard Group Inc grew its stake in shares of Abbott Laboratories by 1.6% during the 3rd quarter. Vanguard Group Inc now owns 139,012,321 shares of the healthcare product maker’s stock worth $10,197,944,000 after acquiring an additional 2,208,781 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Abbott Laboratories by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 139,012,321 shares of the healthcare product maker’s stock worth $10,197,944,000 after acquiring an additional 2,208,781 shares in the last quarter. 74.36% of the stock is owned by institutional investors and hedge funds.

In other Abbott Laboratories news, Director John G. Stratton purchased 3,455 shares of the business’s stock in a transaction on Thursday, January 31st. The stock was acquired at an average price of $72.32 per share, with a total value of $249,865.60. Following the acquisition, the director now directly owns 3,558 shares of the company’s stock, valued at approximately $257,314.56. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website . Also, Chairman Miles D. White sold 142,341 shares of the firm’s stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $72.35, for a total value of $10,298,371.35. Following the sale, the chairman now directly owns 3,459,185 shares of the company’s stock, valued at approximately $250,272,034.75. The disclosure for this sale can be found here . 0.74% of the stock is currently owned by company insiders.

Several equities analysts have recently weighed in on the stock. BTIG Research reaffirmed a “hold” rating on shares of Abbott Laboratories in a research note on Thursday, October 18th. Credit Suisse Group assumed coverage on shares of Abbott Laboratories in a research note on Monday, December 17th. They set an “outperform” rating and a $82.00 price target for the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $80.00 price target on shares of Abbott Laboratories in a research note on Thursday, October 18th. UBS Group assumed coverage on shares of Abbott Laboratories in a research note on Tuesday, November 27th. They set a “buy” rating and a $83.00 price target for the company. Finally, Bank of America reaffirmed a “buy” rating and set a $81.00 price target (up from $73.00) on shares of Abbott Laboratories in a research note on Thursday, February 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and sixteen have given a buy rating to the stock. Abbott Laboratories presently has a consensus rating of “Buy” and an average price target of $79.48.

Shares of NYSE:ABT traded down $0.41 during midday trading on Thursday, hitting $73.97. The stock had a trading volume of 4,864,527 shares, compared to its average volume of 6,926,016. Abbott Laboratories has a 12 month low of $56.81 and a 12 month high of $75.27. The company has a current ratio of 1.42, a quick ratio of 1.13 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $130.64 billion, a PE ratio of 25.68, a P/E/G ratio of 1.95 and a beta of 1.14.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, January 23rd. The healthcare product maker reported $0.81 earnings per share for the quarter, meeting the consensus estimate of $0.81. Abbott Laboratories had a net margin of 7.74% and a return on equity of 16.50%. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.82 billion. During the same period last year, the business earned $0.74 earnings per share. The firm’s revenue was up 2.3% on a year-over-year basis. On average, equities analysts predict that Abbott Laboratories will post 3.2 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 15th. Investors of record on Tuesday, January 15th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Monday, January 14th. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.28. This represents a $1.28 annualized dividend and a dividend yield of 1.73%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 44.44%.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT) Receive News & Ratings for Abbott Laboratories Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Abbott Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter .

Tags:

Click Here to Continue!


Add a Comment

Your email address will not be published. Required fields are marked *